胃癌腹膜转移的外科诊治观

薛侃; 李子禹

doi:10.3969/j.issn.1000-8179.2020.03.645

胃癌腹膜转移的外科诊治观

doi: 10.3969/j.issn.1000-8179.2020.03.645

薛侃,
李子禹^,

恶性肿瘤发病机制及转化研究教育部重点实验室北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤中心一病区(北京市 100142)

基金项目:

吴阶平医学基金会临床科研专项资助项目 320.2710.1811

详细信息

作者简介:
薛侃专业方向为胃癌的外科治疗及综合治疗。E-mail:xuekan@hsc.pku.edu.cn

李子禹教授，主任医师，博士生导师，现任北京大学肿瘤医院胃肠肿瘤中心一病区主任。兼任中华医学会外科学分会胃肠外科学组委员、中国抗癌协会第五届胃癌专业委员会常务委员兼副秘书长、北京抗癌协会第八届理事会常务理事、北京肿瘤学会副理事长等；致力于腹部肿瘤特别是胃、肠道肿瘤的综合诊治，擅长胃、肠肿瘤腹腔镜手术。承担及参与国内外临床试验及国家自然科学基金等多项胃癌研究课题，入选北京市医院管理局“登峰”人才培养计划，北京市卫生系统高层次人才培养计划学科骨干及北京市卫生系统“十百千”卫生人才“百”层次人选。近5年共发表论文50余篇，主编《腹腔镜胃肠手术笔记》

通讯作者:
李子禹, ziyu_li@hsc.pku.edu.cn

计量
- 文章访问数: 138
- HTML全文浏览量: 10
- PDF下载量: 14
- 被引次数: 0
出版历程
- 收稿日期: 2020-01-05
- 刊出日期: 2020-02-15

Diagnosis and surgical treatment of peritoneal metastasis of gastric cancer

Xue Kan,
Li Ziyu^,

Department of Gastrointestinal Surgery, Key laboratory of Carcinogenesis and Translational Research(Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China

Funds:

Wu Jieping Medical Foundation 320.2710.1811

More Information

Corresponding author: Ziyu Li, ziyu_li@hsc.pku.edu.cn

摘要

摘要: 随着诊断性腹腔镜的普及、晚期胃癌转化治疗概念的兴起，以及腹腔化疗港、腹腔热灌注化疗等技术的应用，胃癌腹膜转移的诊断与治疗取得新的进展。然而，胃癌腹膜转移预后差，治疗依旧缺乏高级别证据，在实践过程中应注意规范化诊断与评效，在患者筛选、手术指征、术后化疗等重要问题上进行多学科讨论决策。药物治疗的进展仍是未来提高胃癌腹膜转移预后的关键。
- 胃癌 /
- 腹膜转移 /
- 外科 /
- 诊断 /
- 转化治疗
Abstract: With the prevalence of diagnostic laparoscopy, the concept of conversion therapy in unresectable gastric cancer, as well as the technical application of port implantation and hyperthermic intraperitoneal chemotherapy, new progress has been made in the area of gastric cancer peritoneal metastasis. However, the prognosis for peritoneal metastasis of gastric cancer remains extremely poor, and surgical treatment still lacks high-level evidence. Surgeons should pay attention to standardized diagnosis and evaluation during medical practice, and should conduct multidisciplinary discussions on important issues, such as patient screening, surgical indications, and postoperative chemotherapy. The progress of drug therapy is still the key to improve the prognosis of gastric cancer peritoneal metastasis in the future.
- gastric cancer /
- peritoneal metastasis /
- surgery /
- diagnosis /
- conversion therapy

HTML全文

参考文献(36)

[1]	Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial):a phase Ⅲtrial[J]. Lancet Oncol, 2008, 9(3):215-221. https://www.ncbi.nlm.nih.gov/pubmed/18282805/
[2]	Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study:the FLAGS trial[J]. J Clin Oncol, 2010, 28(9):1547-1553. https://www.ncbi.nlm.nih.gov/pubmed/20159816
[3]	Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014(ver. 4)[J]. Gastric Cancer, 2017, 20(1):1-19. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=d2734fa789c88501ec4c3600d28d52ff
[4]	National Comprehensive Cancer Network. NCCN Guidelines Gastric Cancer Version 4. 2019[R/OL]. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
[5]	Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases:Progress toward a new standard of care[J]. Cancer Treat Rev, 2016, 48:42-49. http://cn.bing.com/academic/profile?id=03048d0ed8b802e7aaed9f7179a5e901&encoded=0&v=paper_preview&mkt=zh-cn
[6]	薛侃, 李子禹, 李双喜, 等.腹腔镜热灌注化疗联合腹腔及系统化疗转化治疗胃癌腹膜转移病人1例报告[J].中国实用外科杂志, 2017, 37(10):67-70.
[7]	严超, 石红鹏, 刘瑩, 等.胃癌腹膜转移的新辅助腹腔内联合全身化疗:初步研究[J].外科理论与实践, 2017, 22(1):32-39.
[8]	李子禹, 薛侃, 季加孚.晚期胃癌手术治疗价值及合理应用[J].中国实用外科杂志, 2017, 37(10):1073-1077. http://d.old.wanfangdata.com.cn/Periodical/zgsyyy201921024
[9]	Wang Z, Chen JQ. Imaging in assessing hepatic and peritoneal metastases of gastric cancer:a systematic review[J]. BMC Gastroenterol, 2011, 11:19. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_66ca12b691abe7f82871eaa0aa92f509
[10]	Kim SJ, Kim HH, Kim YH, et al. Peritoneal metastasis:detection with 16-or 64-detector row CT in patients undergoing surgery for gastric cancer[J]. Radiology, 2009, 253(2):407-415. http://cn.bing.com/academic/profile?id=eefe8bdd28e8337eea86aa6f891f0403&encoded=0&v=paper_preview&mkt=zh-cn
[11]	中国抗癌协会胃癌专业委员会.胃癌腹膜转移防治中国专家共识[J].中国普通外科学文献, 2017, 11(5):289-297. http://d.old.wanfangdata.com.cn/Periodical/zjyx201715001
[12]	Dong, L Tang, ZY Li, et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer[J]. Ann Oncol, 2019, 30(3):431-438. http://cn.bing.com/academic/profile?id=7131a5edbc6c8f979c4d32d2f3914600&encoded=0&v=paper_preview&mkt=zh-cn
[13]	Ziyu LI, Zhemin LI, SQ JIA, et al. Depth of tumor invasion and tumoroccupied portions of stomach are predictive factors of intra-abdominal metastasis[J]. Chin J Cancer Res, 2017, 29(2):109-117. http://europepmc.org/articles/PMC5422412
[14]	Masaki Nakamura, Toshiyasu Ojima, Mikihito Nakamori, et al. Conversion Surgery for Gastric Cancer with Peritoneal Metastasis Based on the Diagnosis of Second-Look Staging Laparoscopy[J]. J Gastrointest Surg, 2019, 23(9):1758-1766. http://cn.bing.com/academic/profile?id=6ae3e992e197b9d3951fcd4daa8c357b&encoded=0&v=paper_preview&mkt=zh-cn
[15]	H Ishigami, J Kitayama, S Kaisaki, et al. Phase Ⅱ study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis[J]. Ann Oncol, 2010, 21(1):67-70. https://www.jstage.jst.go.jp/article/jjgs/45/11/45_45.1137/_article/references
[16]	薛侃, 李子禹.浅析腹腔化疗港在胃癌腹膜转移治疗中的应用[J].国际外科学杂志, 2018, 45(4):217-220. http://d.old.wanfangdata.com.cn/Periodical/gwyx-wkxfc201804001
[17]	Hasovits C, Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics[J]. Clin Pharmacokinet, 2012, 51(4):203-224. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=57f01e4f0b48e1d7179129002b12b25c
[18]	Ishigami H, Fujiwara Y, Fukushima R, et al. Phase Ⅲtrial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus s-1 in patients with gastric cancer with peritoneal metastasis:PHOENIX-GC Trial[J]. J Clin Oncol, 2018, 36(19):1922-1929. http://paper.medlive.cn/literature/3005850
[19]	Li ZY, Xue K, Ying XJ, et al. PHOENIX-GC trial:underpowered for significant results[J]?J Clin Oncol, 2019, 37(2):167. http://cn.bing.com/academic/profile?id=3d61fa42e08f271fef57b61fcd3ceb00&encoded=0&v=paper_preview&mkt=zh-cn
[20]	Fujiwara Y, Ishigami H, Miwa H, et al. Phase Ⅱ study of intraperitoneal paclitaxel plus S-1/oxaliplatin for gastric cancer with peritoneal metastasis:SOX+IP PTX trial[J]. J Clin Oncol, 2016, 34(Suppl 15):4040. https://www.researchgate.net/publication/327492129_Phase_II_study_of_intraperitoneal_paclitaxel_plus_S-1oxaliplatin_for_gastric_cancer_with_peritoneal_metastasis_SOXIP_PTX_trial
[21]	Dexter Yak Seng Chan, Nicholas Li-Xun Syn, Rachel Yap, et al. Conversion surgery post-intraperitoneal paclitaxel and systemic chemotherapy for gastric cancer carcinomatosis peritonei. Are we ready[J]?J Gastrointest Surg, 2017, 21(3):425-433. http://cn.bing.com/academic/profile?id=edd13838ac669fe47c372a1634a922df&encoded=0&v=paper_preview&mkt=zh-cn
[22]	Fujiwara Y, Takiguchi S, Nakajima K, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination[J]. J Surg Oncol, 2012, 105(1):38-42. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=ea57dd8a64b2f7353efab2f5cfffb57e
[23]	薛侃, 李子禹, 闫国军, 等.腹腔化疗港在胃癌腹膜转移中应用的安全性分析[J].中国肿瘤临床, 2019, 46(1):34-38. http://journal11.magtechjournal.com/Jwk_zgzllc/CN/abstract/abstract14067.shtml
[24]	Emoto S, Ishigami H, Hidemura A, et al. Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis[J]. Jpn J Clin Oncol, 2012, 42(11):1013-1019. http://cn.bing.com/academic/profile?id=1610ac074d926c27790461fee7d81212&encoded=0&v=paper_preview&mkt=zh-cn
[25]	Li Y, Zhou YF, Liang H, et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies[J]. World J Gastroenterol, 2016, 22(30):6906-6916. http://cn.bing.com/academic/profile?id=f6a2362edfad8c95518f231029e8719c&encoded=0&v=paper_preview&mkt=zh-cn
[26]	Yonemura Y, Canbay E, Li Y, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent[J]. Eur J Surg Oncol, 2016, 42(8):1123-1131. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=7a8de6d12d26024cf5857f10e75288cd
[27]	Coccolini F, Catena F, Glehen O, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis[J]. Eur J Surg Oncol, 2015, 41(7):911-919. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=f06cc9c519b6d9c148473021f53e31a8
[28]	Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study):A Propensity Score Analysis[J]. J Clin Oncol, 2019, 37(23):2028-2040. http://cn.bing.com/academic/profile?id=7f5d435389358fefd035b2a7c5a6883c&encoded=0&v=paper_preview&mkt=zh-cn
[29]	Rudloff U, Langan RC, Mullinax JE, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin:results of the GYMSSA trial[J]. J Surg Oncol, 2014, 110(3):275-284. http://cn.bing.com/academic/profile?id=8933d5484a485387e2b2a4c68440acbd&encoded=0&v=paper_preview&mkt=zh-cn
[30]	Ji ZH, Peng KW, Yu Y, et al. Current status and future prospects of clinical trials on CRS+HIPEC for gastric cancer peritoneal metastases[J]. Int J Hyperthermia, 2017, 33(5):562-570. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1080/02656736.2017.1283065
[31]	Koemans WJ, Kaaij van der RT, Boot H, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE Ⅱ)[J]. BMC Cancer, 2019, 19(1):420. doi: 10.1186/s12885-019-5640-2
[32]	Al-Batran SE, Goetze TO, Mueller DW, et al. The RENAISSANCE (AIOFLOT5) trial:effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction-a phase Ⅲ trial of the German AIO/CAO-V/CAOGI[J]. BMC Cancer, 2017, 17(1):893.
[33]	Yoshida K, Yamaguchi K, Okumura N, et al. Is conversion therapy possible in stage Ⅳ gastric cancer:the proposal of new biological categories of classification[J]. Gastric Cancer, 2016, 19(2):329-338. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824831/
[34]	李子禹, 薛侃, 季加孚.晚期胃癌转化治疗中基于手术的分型[J].中华胃肠外科杂志, 2017, 20(7):721-725. http://d.old.wanfangdata.com.cn/Periodical/zgwcwkzz201707001
[35]	Ishigami H, Yamaguchi H, Yamashita H, et al. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings[J]. Gastric Cancer, 2017, 20(Suppl 1):128-134. http://d.old.wanfangdata.com.cn/Periodical/wjg200546027
[36]	Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA):a phase 3, randomised controlled trial[J]. Lancet Oncol, 2016, 17(3):309-318. http://cn.bing.com/academic/profile?id=c9c15318422346a63acccd0d83f2fddd&encoded=0&v=paper_preview&mkt=zh-cn